Staidson Beijing Biopharma (300204) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.046x

Based on the latest financial reports, Staidson Beijing Biopharma (300204) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-39.18 Million ≈ $-5.73 Million USD) by net assets (CN¥859.70 Million ≈ $125.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Staidson Beijing Biopharma - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Staidson Beijing Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300204 current and long-term liabilities for a breakdown of total debt and financial obligations.

Staidson Beijing Biopharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Staidson Beijing Biopharma ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Jiangxi Hongcheng Waterworks Co Ltd SHG:600461	0.058x
Wuxi Dk Electronic Materials Co Ltd SHE:300842	0.002x
Sanbo Hospital Management Group Ltd. A SHE:301293	N/A
G2 Goldfields Inc. TO:GTWO	-0.013x
Apex Dynamics Inc. TW:4583	0.022x
Qingdao NovelBeam Technology Co. Ltd. A SHG:688677	0.013x
Cal-Comp Electronics (Thailand) Public Company Limited TW:9105	0.024x
Stolt-Nielsen Limited LSE:0OHK	0.058x

Annual Cash Flow Conversion Efficiency for Staidson Beijing Biopharma (2007–2024)

The table below shows the annual cash flow conversion efficiency of Staidson Beijing Biopharma from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Staidson Beijing Biopharma market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥916.76 Million ≈ $134.15 Million	CN¥-63.68 Million ≈ $-9.32 Million	-0.069x	+68.83%
2023-12-31	CN¥1.02 Billion ≈ $149.36 Million	CN¥-227.47 Million ≈ $-33.29 Million	-0.223x	-71.83%
2022-12-31	CN¥1.35 Billion ≈ $198.11 Million	CN¥-175.60 Million ≈ $-25.70 Million	-0.130x	-24.10%
2021-12-31	CN¥1.55 Billion ≈ $226.92 Million	CN¥-162.07 Million ≈ $-23.72 Million	-0.105x	-44.78%
2020-12-31	CN¥1.59 Billion ≈ $232.30 Million	CN¥-114.60 Million ≈ $-16.77 Million	-0.072x	-366.21%
2019-12-31	CN¥1.64 Billion ≈ $239.29 Million	CN¥44.34 Million ≈ $6.49 Million	0.027x	-59.63%
2018-12-31	CN¥2.46 Billion ≈ $359.66 Million	CN¥165.08 Million ≈ $24.16 Million	0.067x	-45.77%
2017-12-31	CN¥2.21 Billion ≈ $323.30 Million	CN¥273.64 Million ≈ $40.04 Million	0.124x	+11.78%
2016-12-31	CN¥1.92 Billion ≈ $280.70 Million	CN¥212.55 Million ≈ $31.10 Million	0.111x	-19.24%
2015-12-31	CN¥1.68 Billion ≈ $246.39 Million	CN¥231.01 Million ≈ $33.80 Million	0.137x	+0.44%
2014-12-31	CN¥1.51 Billion ≈ $221.60 Million	CN¥206.85 Million ≈ $30.27 Million	0.137x	+61.17%
2013-12-31	CN¥1.31 Billion ≈ $192.28 Million	CN¥111.36 Million ≈ $16.30 Million	0.085x	+16.61%
2012-12-31	CN¥1.24 Billion ≈ $181.57 Million	CN¥90.19 Million ≈ $13.20 Million	0.073x	-7.94%
2011-12-31	CN¥1.10 Billion ≈ $161.27 Million	CN¥87.01 Million ≈ $12.73 Million	0.079x	-79.46%
2010-12-31	CN¥166.23 Million ≈ $24.32 Million	CN¥63.91 Million ≈ $9.35 Million	0.384x	+8.64%
2009-12-31	CN¥119.72 Million ≈ $17.52 Million	CN¥42.37 Million ≈ $6.20 Million	0.354x	+36.99%
2008-12-31	CN¥62.82 Million ≈ $9.19 Million	CN¥16.23 Million ≈ $2.37 Million	0.258x	+61.81%
2007-12-31	CN¥33.87 Million ≈ $4.96 Million	CN¥5.41 Million ≈ $791.30K	0.160x	--

About Staidson Beijing Biopharma

SHE:300204 China Biotechnology

Market Cap

$1.93 Billion

CN¥13.20 Billion CNY

Market Cap Rank

#6406 Global

#1438 in China

Share Price

CN¥27.63

Change (1 day)

-0.79%

52-Week Range

CN¥10.31 - CN¥61.00

All Time High

CN¥61.00